Sintetica SA

New molecular entities had a rough week at the US FDA, as the agency issued a complete response letter for Gilead Sciences, Inc. ’s bulevirtide for hepatitis delta virus infection, CytoDyn, Inc. wi

A US FDA green light for Karyopharm Therapeutics Inc. 's selinexor seemed highly unlikely following a February advisory committee meeting, but the company may have a reason to hope for approval, as t